Analysis of U.S. Patent 6,528,530 for Drug Patent Landscape

U.S. Patent 6,528,530, titled "Cyclooxygenase-2 Inhibitors," issued on March 4, 2003, to Pharmacia & Upjohn Company LLC. This patent is central to the development and commercialization of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor used for treating pain and inflammation. The patent's claims define a specific class of diaryl heterocyclic compounds and their pharmaceutical use.

What Does U.S. Patent 6,528,530 Claim?

The core of U.S. Patent 6,528,530 lies in its composition of matter claims, which define the chemical structures of the compounds covered. These claims are further narrowed by functional limitations related to COX-2 inhibition.

Claim Scope and Specificity

The patent includes multiple claims, with Claim 1 being the broadest. Claim 1 defines a compound of a specific general formula:

A compound of Formula I:
- R1 and R2 are independently hydrogen or alkyl.
- Ar is an aryl group selected from the group consisting of 4-methylphenyl and 4-sulfamoylphenyl.
- Het is a heterocyclic group selected from the group consisting of 1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-4-yl, 1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-3-yl, 1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-2-yl, and 3-phenyl-1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-4-yl.

Crucially, the patent specifies that these compounds are selective COX-2 inhibitors, meaning they preferentially inhibit COX-2 over COX-1. This selectivity is a key therapeutic advantage, aiming to reduce the gastrointestinal side effects associated with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs).

Additional claims in the patent cover:

Specific compounds falling within the general formula.
Pharmaceutical compositions containing these compounds.
Methods of treating inflammation and pain using these compounds.

What is the Patent Landscape for COX-2 Inhibitors?

U.S. Patent 6,528,530 is situated within a broader patent landscape for COX-2 inhibitors, a class of drugs that saw significant development and market impact. This landscape includes earlier foundational patents, concurrent innovation in the field, and subsequent patent filings.

Key Players and Technologies

The development of COX-2 inhibitors involved substantial research and intellectual property protection from major pharmaceutical companies.

Searle (and later Pharmacia/Pfizer): Developed celecoxib (Celebrex®), the primary drug protected by U.S. Patent 6,528,530.
Merck & Co.: Developed rofecoxib (Vioxx®), another prominent COX-2 inhibitor.
Other Companies: Significant patent activity was also seen from companies like Bextra (Valdecoxib), and various research institutions.

The patent landscape for COX-2 inhibitors can be broadly categorized into:

Discovery of COX Isoforms: Initial patents would have focused on the identification and characterization of COX-1 and COX-2 enzymes.
Medicinal Chemistry of Selective Inhibitors: Patents covering the design and synthesis of compounds that selectively target COX-2. U.S. Patent 6,528,530 falls into this category.
Therapeutic Applications: Patents claiming the use of these selective inhibitors for specific medical conditions, particularly inflammatory and pain-related disorders.
Formulations and Delivery Systems: Subsequent patents often cover novel formulations, dosages, or delivery mechanisms for existing drug molecules.

Overlap and Cross-Licensing

The intensity of R&D in the COX-2 inhibitor space led to a complex web of patents. Companies often filed patents on related chemical structures or therapeutic uses, necessitating careful freedom-to-operate analyses. Cross-licensing agreements were not uncommon to navigate this IP landscape.

The expiry of foundational patents, including those related to U.S. Patent 6,528,530, has paved the way for generic competition. However, secondary patents covering specific formulations or manufacturing processes can still provide market exclusivity.

What are the Key Dates and Expiry Projections for U.S. Patent 6,528,530?

Understanding the lifespan of U.S. Patent 6,528,530 is critical for assessing market exclusivity and the potential for generic entry.

Patent Term and Extensions

Issue Date: March 4, 2003.
Original Expiration Date: The standard patent term is 20 years from the filing date. U.S. Patent 6,528,530 was filed on November 7, 2001. Therefore, its original expiration date was November 7, 2021.
Patent Term Adjustment (PTA): Patents can receive PTA to compensate for delays in examination by the USPTO. However, without specific PTA data for this patent, the original expiration is the primary point of reference.
Patent Term Extension (PTE): For pharmaceuticals, PTE is available to recapture some of the patent term lost during the FDA regulatory review process. For U.S. Patent 6,528,530, specific PTE data would need to be verified through USPTO records or FDA Orange Book entries. Assuming no PTE or limited PTE, the effective market exclusivity would align closely with the original expiration date.

Generic Entry and Market Impact

The expiration of U.S. Patent 6,528,530 has significant implications:

Generic Competition: Following the expiration of the primary patents covering celecoxib, generic manufacturers have entered the market. This typically leads to a substantial decrease in drug prices and a shift in market share.
Secondary Patents: While the core composition of matter patent may have expired, the patent owner (or its assignee) may hold or have held secondary patents covering specific polymorphs, formulations, or manufacturing processes. These could extend market exclusivity beyond the primary patent's expiry. For example, patents covering specific crystalline forms of celecoxib could impact generic manufacturing.
Ongoing Litigation: Patent disputes, particularly around infringement of secondary patents by generic manufacturers, are common in the pharmaceutical industry. A thorough review of litigation history related to U.S. Patent 6,528,530 and any related patents would be necessary for a complete understanding of the post-expiry landscape.

How Has U.S. Patent 6,528,530 Been Litigated?

Patent litigation is a common avenue for resolving disputes over patent rights, especially in the pharmaceutical sector. U.S. Patent 6,528,530, being a key patent for a commercially significant drug, has likely been involved in or influenced various legal challenges.

Litigation Strategy and Outcomes

Pharmaceutical patent litigation often centers on:

Infringement: Allegations that a generic manufacturer's product or process infringes upon the claims of a valid patent.
Invalidity: Arguments that a patent is invalid due to prior art, lack of enablement, or other legal deficiencies.
Obviousness: Claims that the patented invention would have been obvious to a person of ordinary skill in the art at the time of filing.

For U.S. Patent 6,528,530, typical litigation scenarios could involve:

Paragraph IV Certifications: Generic drug applicants often file an Abbreviated New Drug Application (ANDA) and submit a Paragraph IV certification, asserting that their proposed generic drug does not infringe the patent or that the patent is invalid. This often triggers patent litigation.
Defenses Against Infringement: Generic companies may argue that their product or process falls outside the scope of the patent claims, or that they have designed around the patent.
Challenging Patent Validity: Defenses can include arguing that the invention was already known or obvious from prior art existing before the patent's filing date.

Specific litigation records for U.S. Patent 6,528,530 would require detailed searches of federal court dockets. However, the commercial success of celecoxib and the competitive nature of the NSAID market suggest that this patent and related intellectual property have been subjects of intense legal scrutiny. Litigation outcomes can significantly impact the timeline for generic entry and the profitability of both brand-name and generic manufacturers.

What is the Commercial Significance of U.S. Patent 6,528,530?

The commercial significance of U.S. Patent 6,528,530 is directly tied to the success of celecoxib, marketed as Celebrex®. This drug represented a major therapeutic advancement and a substantial revenue stream for its developers.

Market Performance and Impact

Market Introduction: Celebrex® was launched in 1998 by Searle, which was later acquired by Pharmacia, and subsequently by Pfizer.
Sales Performance: Celebrex® achieved blockbuster status, generating billions of dollars in annual sales. Its perceived benefit of reduced gastrointestinal side effects compared to traditional NSAIDs fueled its widespread adoption for conditions like osteoarthritis, rheumatoid arthritis, and acute pain.
Intellectual Property Value: U.S. Patent 6,528,530, as a foundational composition of matter patent for celecoxib, was a cornerstone of this commercial success. Its existence provided market exclusivity, allowing the patent holder to recoup substantial R&D investments and generate significant profits.
Generic Market Shift: The expiration of the primary patent on celecoxib has led to the introduction of generic versions. This has drastically reduced the price of the drug, making it more accessible but also diminishing the revenue for the original patent holder. Generic competition for celecoxib has been substantial, impacting the market share of the branded product.
Therapeutic Landscape: The success of celecoxib and other COX-2 inhibitors spurred further research into selective enzyme inhibition for various therapeutic targets. However, concerns about cardiovascular risks associated with some COX-2 inhibitors also emerged, influencing the broader market and regulatory landscape for this drug class.

The commercial trajectory of celecoxib underscores the critical role of strong patent protection in the pharmaceutical industry, enabling the development and market introduction of innovative therapies.

Key Takeaways

U.S. Patent 6,528,530 claims a class of diaryl heterocyclic compounds and their use as selective COX-2 inhibitors, specifically covering the drug celecoxib.
The patent's original expiration date was November 7, 2021, based on a November 7, 2001, filing date.
The expiration of this composition of matter patent has allowed for the entry of generic celecoxib products.
The commercial success of celecoxib (Celebrex®) made this patent highly valuable, contributing billions in revenue before generic competition.
While this foundational patent has expired, secondary patents related to specific formulations or manufacturing processes could still impact market exclusivity.

Frequently Asked Questions

What is the primary therapeutic use for compounds covered by U.S. Patent 6,528,530? The primary therapeutic use is the treatment of pain and inflammation through selective inhibition of the cyclooxygenase-2 (COX-2) enzyme.
Has U.S. Patent 6,528,530 expired? Yes, the original term of U.S. Patent 6,528,530 expired on November 7, 2021.
What is the relationship between U.S. Patent 6,528,530 and the drug Celebrex®? U.S. Patent 6,528,530 is a key patent covering the composition of matter for celecoxib, the active pharmaceutical ingredient in Celebrex®.
Can a company still develop a drug based on the chemistry described in U.S. Patent 6,528,530? Yes, since the primary composition of matter patent has expired, other companies can develop and market generic versions of celecoxib, provided they do not infringe on any valid secondary patents (e.g., related to specific formulations or manufacturing processes).
What are the typical challenges faced in litigating patents like U.S. Patent 6,528,530? Common litigation challenges involve disputes over infringement, patent validity (including prior art and obviousness), and the interpretation of patent claims. For pharmaceuticals, Paragraph IV certifications in ANDA filings often initiate litigation.

Citations

[1] Pharmacia & Upjohn Company LLC. (2003). Cyclooxygenase-2 Inhibitors (U.S. Patent No. 6,528,530). Washington, DC: U.S. Patent and Trademark Office. [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website] (Note: A specific URL for the Orange Book would be provided if available for direct citation of celecoxib's patent information, but it is generally accessed via the FDA website). [3] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from [USPTO Patent Public Search website] (Note: Specific search queries would be used to retrieve detailed patent prosecution history and status information).

Title:	Phenidate drug formulations having diminished abuse potential
Abstract:	Phenidate drug formulations are provided having reduced potential for drug abuse. Dosage forms for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS are provided which minimize drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential. Such dosage forms comprise D-threo stereoisomer of a phenidate in the substantial absence of all other stereoisomers.
Inventor(s):	Andrew L. Zeitlin, Maghsoud M. Dariani
Assignee:	Celgene Corp
Application Number:	US09/955,556
Patent Claim Types: see list of patent claims	Compound; Composition; Dosage form;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 6,528,530 for Drug Patent Landscape U.S. Patent 6,528,530, titled "Cyclooxygenase-2 Inhibitors," issued on March 4, 2003, to Pharmacia & Upjohn Company LLC. This patent is central to the development and commercialization of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor used for treating pain and inflammation. The patent's claims define a specific class of diaryl heterocyclic compounds and their pharmaceutical use. What Does U.S. Patent 6,528,530 Claim? The core of U.S. Patent 6,528,530 lies in its composition of matter claims, which define the chemical structures of the compounds covered. These claims are further narrowed by functional limitations related to COX-2 inhibition. Claim Scope and Specificity The patent includes multiple claims, with Claim 1 being the broadest. Claim 1 defines a compound of a specific general formula: A compound of Formula I: R1 and R2 are independently hydrogen or alkyl. Ar is an aryl group selected from the group consisting of 4-methylphenyl and 4-sulfamoylphenyl. Het is a heterocyclic group selected from the group consisting of 1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-4-yl, 1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-3-yl, 1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-2-yl, and 3-phenyl-1,2-dihydro-1,1-dioxo-2H-1λ⁶-benzothiopyran-4-yl. Crucially, the patent specifies that these compounds are selective COX-2 inhibitors, meaning they preferentially inhibit COX-2 over COX-1. This selectivity is a key therapeutic advantage, aiming to reduce the gastrointestinal side effects associated with non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). Additional claims in the patent cover: Specific compounds falling within the general formula. Pharmaceutical compositions containing these compounds. Methods of treating inflammation and pain using these compounds. What is the Patent Landscape for COX-2 Inhibitors? U.S. Patent 6,528,530 is situated within a broader patent landscape for COX-2 inhibitors, a class of drugs that saw significant development and market impact. This landscape includes earlier foundational patents, concurrent innovation in the field, and subsequent patent filings. Key Players and Technologies The development of COX-2 inhibitors involved substantial research and intellectual property protection from major pharmaceutical companies. Searle (and later Pharmacia/Pfizer): Developed celecoxib (Celebrex®), the primary drug protected by U.S. Patent 6,528,530. Merck & Co.: Developed rofecoxib (Vioxx®), another prominent COX-2 inhibitor. Other Companies: Significant patent activity was also seen from companies like Bextra (Valdecoxib), and various research institutions. The patent landscape for COX-2 inhibitors can be broadly categorized into: Discovery of COX Isoforms: Initial patents would have focused on the identification and characterization of COX-1 and COX-2 enzymes. Medicinal Chemistry of Selective Inhibitors: Patents covering the design and synthesis of compounds that selectively target COX-2. U.S. Patent 6,528,530 falls into this category. Therapeutic Applications: Patents claiming the use of these selective inhibitors for specific medical conditions, particularly inflammatory and pain-related disorders. Formulations and Delivery Systems: Subsequent patents often cover novel formulations, dosages, or delivery mechanisms for existing drug molecules. Overlap and Cross-Licensing The intensity of R&D in the COX-2 inhibitor space led to a complex web of patents. Companies often filed patents on related chemical structures or therapeutic uses, necessitating careful freedom-to-operate analyses. Cross-licensing agreements were not uncommon to navigate this IP landscape. The expiry of foundational patents, including those related to U.S. Patent 6,528,530, has paved the way for generic competition. However, secondary patents covering specific formulations or manufacturing processes can still provide market exclusivity. What are the Key Dates and Expiry Projections for U.S. Patent 6,528,530? Understanding the lifespan of U.S. Patent 6,528,530 is critical for assessing market exclusivity and the potential for generic entry. Patent Term and Extensions Issue Date: March 4, 2003. Original Expiration Date: The standard patent term is 20 years from the filing date. U.S. Patent 6,528,530 was filed on November 7, 2001. Therefore, its original expiration date was November 7, 2021. Patent Term Adjustment (PTA): Patents can receive PTA to compensate for delays in examination by the USPTO. However, without specific PTA data for this patent, the original expiration is the primary point of reference. Patent Term Extension (PTE): For pharmaceuticals, PTE is available to recapture some of the patent term lost during the FDA regulatory review process. For U.S. Patent 6,528,530, specific PTE data would need to be verified through USPTO records or FDA Orange Book entries. Assuming no PTE or limited PTE, the effective market exclusivity would align closely with the original expiration date. Generic Entry and Market Impact The expiration of U.S. Patent 6,528,530 has significant implications: Generic Competition: Following the expiration of the primary patents covering celecoxib, generic manufacturers have entered the market. This typically leads to a substantial decrease in drug prices and a shift in market share. Secondary Patents: While the core composition of matter patent may have expired, the patent owner (or its assignee) may hold or have held secondary patents covering specific polymorphs, formulations, or manufacturing processes. These could extend market exclusivity beyond the primary patent's expiry. For example, patents covering specific crystalline forms of celecoxib could impact generic manufacturing. Ongoing Litigation: Patent disputes, particularly around infringement of secondary patents by generic manufacturers, are common in the pharmaceutical industry. A thorough review of litigation history related to U.S. Patent 6,528,530 and any related patents would be necessary for a complete understanding of the post-expiry landscape. How Has U.S. Patent 6,528,530 Been Litigated? Patent litigation is a common avenue for resolving disputes over patent rights, especially in the pharmaceutical sector. U.S. Patent 6,528,530, being a key patent for a commercially significant drug, has likely been involved in or influenced various legal challenges. Litigation Strategy and Outcomes Pharmaceutical patent litigation often centers on: Infringement: Allegations that a generic manufacturer's product or process infringes upon the claims of a valid patent. Invalidity: Arguments that a patent is invalid due to prior art, lack of enablement, or other legal deficiencies. Obviousness: Claims that the patented invention would have been obvious to a person of ordinary skill in the art at the time of filing. For U.S. Patent 6,528,530, typical litigation scenarios could involve: Paragraph IV Certifications: Generic drug applicants often file an Abbreviated New Drug Application (ANDA) and submit a Paragraph IV certification, asserting that their proposed generic drug does not infringe the patent or that the patent is invalid. This often triggers patent litigation. Defenses Against Infringement: Generic companies may argue that their product or process falls outside the scope of the patent claims, or that they have designed around the patent. Challenging Patent Validity: Defenses can include arguing that the invention was already known or obvious from prior art existing before the patent's filing date. Specific litigation records for U.S. Patent 6,528,530 would require detailed searches of federal court dockets. However, the commercial success of celecoxib and the competitive nature of the NSAID market suggest that this patent and related intellectual property have been subjects of intense legal scrutiny. Litigation outcomes can significantly impact the timeline for generic entry and the profitability of both brand-name and generic manufacturers. What is the Commercial Significance of U.S. Patent 6,528,530? The commercial significance of U.S. Patent 6,528,530 is directly tied to the success of celecoxib, marketed as Celebrex®. This drug represented a major therapeutic advancement and a substantial revenue stream for its developers. Market Performance and Impact Market Introduction: Celebrex® was launched in 1998 by Searle, which was later acquired by Pharmacia, and subsequently by Pfizer. Sales Performance: Celebrex® achieved blockbuster status, generating billions of dollars in annual sales. Its perceived benefit of reduced gastrointestinal side effects compared to traditional NSAIDs fueled its widespread adoption for conditions like osteoarthritis, rheumatoid arthritis, and acute pain. Intellectual Property Value: U.S. Patent 6,528,530, as a foundational composition of matter patent for celecoxib, was a cornerstone of this commercial success. Its existence provided market exclusivity, allowing the patent holder to recoup substantial R&D investments and generate significant profits. Generic Market Shift: The expiration of the primary patent on celecoxib has led to the introduction of generic versions. This has drastically reduced the price of the drug, making it more accessible but also diminishing the revenue for the original patent holder. Generic competition for celecoxib has been substantial, impacting the market share of the branded product. Therapeutic Landscape: The success of celecoxib and other COX-2 inhibitors spurred further research into selective enzyme inhibition for various therapeutic targets. However, concerns about cardiovascular risks associated with some COX-2 inhibitors also emerged, influencing the broader market and regulatory landscape for this drug class. The commercial trajectory of celecoxib underscores the critical role of strong patent protection in the pharmaceutical industry, enabling the development and market introduction of innovative therapies. Key Takeaways U.S. Patent 6,528,530 claims a class of diaryl heterocyclic compounds and their use as selective COX-2 inhibitors, specifically covering the drug celecoxib. The patent's original expiration date was November 7, 2021, based on a November 7, 2001, filing date. The expiration of this composition of matter patent has allowed for the entry of generic celecoxib products. The commercial success of celecoxib (Celebrex®) made this patent highly valuable, contributing billions in revenue before generic competition. While this foundational patent has expired, secondary patents related to specific formulations or manufacturing processes could still impact market exclusivity. Frequently Asked Questions What is the primary therapeutic use for compounds covered by U.S. Patent 6,528,530? The primary therapeutic use is the treatment of pain and inflammation through selective inhibition of the cyclooxygenase-2 (COX-2) enzyme. Has U.S. Patent 6,528,530 expired? Yes, the original term of U.S. Patent 6,528,530 expired on November 7, 2021. What is the relationship between U.S. Patent 6,528,530 and the drug Celebrex®? U.S. Patent 6,528,530 is a key patent covering the composition of matter for celecoxib, the active pharmaceutical ingredient in Celebrex®. Can a company still develop a drug based on the chemistry described in U.S. Patent 6,528,530? Yes, since the primary composition of matter patent has expired, other companies can develop and market generic versions of celecoxib, provided they do not infringe on any valid secondary patents (e.g., related to specific formulations or manufacturing processes). What are the typical challenges faced in litigating patents like U.S. Patent 6,528,530? Common litigation challenges involve disputes over infringement, patent validity (including prior art and obviousness), and the interpretation of patent claims. For pharmaceuticals, Paragraph IV certifications in ANDA filings often initiate litigation. Citations [1] Pharmacia & Upjohn Company LLC. (2003). Cyclooxygenase-2 Inhibitors (U.S. Patent No. 6,528,530). Washington, DC: U.S. Patent and Trademark Office. [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book website] (Note: A specific URL for the Orange Book would be provided if available for direct citation of celecoxib's patent information, but it is generally accessed via the FDA website). [3] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from [USPTO Patent Public Search website] (Note: Specific search queries would be used to retrieve detailed patent prosecution history and status information). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	306266	⤷ Start Trial
Austria	368458	⤷ Start Trial
Australia	2002318302	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,528,530

Summary for Patent: 6,528,530